<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39291052</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2052-3211</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of pharmaceutical policy and practice</Title><ISOAbbreviation>J Pharm Policy Pract</ISOAbbreviation></Journal><ArticleTitle>Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.</ArticleTitle><Pagination><StartPage>2399716</StartPage><MedlinePgn>2399716</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2399716</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/20523211.2024.2399716</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">This study aimed to determine the association of Torsade de Pointes (TdP) with anxiolytic drugs and present a detailed overview of anxiolytic-induced cases of TdP reported to the Food and Drug Administration Adverse Event Reporting System (FAERS).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">All cases of anxiolytic-induced TdP (<i>n</i> = 260) between 1990 and 2020 were retrieved from the FAERS database using the Preferred Term 'Torsade de Pointes, code: 10044066' from the Medical Dictionary for Regulatory Activities (MedDRA version 22). Four data-mining algorithms were used for disproportionality analysis: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Empirical Bayes Geometric Mean (EBGM), and Information Content (IC). Anxiolytics with ≥3 TdP cases were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of a total of eight drugs, this study identified seven signals of TdP, of which six signals were new, namely for alprazolam, bromazepam, lorazepam, meprobamate, midazolam, and oxazepam. Based on disproportionality analysis, among new signals, the highest risk of TdP was observed with bromazepam and midazolam. Alprazolam showed the lowest risk for TdP, while diazepam did not reach significant disproportionality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study identified six new signals of TdP among anxiolytic drugs, so warranting stringent clinical studies to ascertain the actual risk of TdP and ensure patient safety.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="UNASSIGNED">This study is registered at ClinicalTrials.gov (NCT.gov ID: NCT04293432).</AbstractText><CopyrightInformation>© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Zahid</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehman</LastName><ForeName>Inayat Ur</ForeName><Initials>IU</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Abdul Wali Khan University, Mardan, Pakistan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Practice, Universiti Malaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Khang Wen</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razi</LastName><ForeName>Pakhrur</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center of Disaster Monitoring and Earth Observation, Physics Department, Universitas Negeri Padang, Padang, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ming</LastName><ForeName>Long Chiau</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-6971-1383</Identifier><AffiliationInfo><Affiliation>School of Medical and Life Sciences, Sunway University, Sunway City, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04293432</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pharm Policy Pract</MedlineTA><NlmUniqueID>101627192</NlmUniqueID><ISSNLinking>2052-3211</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Medicine</Keyword><Keyword MajorTopicYN="N">Patient Safety</Keyword><Keyword MajorTopicYN="N">cardiology</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">disproportionality analysis</Keyword><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">human and disease</Keyword><Keyword MajorTopicYN="N">patient safety</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">preventable death</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39291052</ArticleId><ArticleId IdType="pmc">PMC11407426</ArticleId><ArticleId IdType="doi">10.1080/20523211.2024.2399716</ArticleId><ArticleId IdType="pii">2399716</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ali, Z., Ismail, M., Khan, F., &amp; Sajid, H. (2021). Association of H1-antihistamines with Torsade de Pointes: A pharmacovigilance study of the food and drug administration adverse event reporting system. Expert Opinion on Drug Safety, 20(1), 101–108. 10.1080/14740338.2021.1846717</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2021.1846717</ArticleId><ArticleId IdType="pubmed">33141610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, Z., Ismail, M., Nazar, Z., Khan, F., Khan, Q., &amp; Noor, S. (2020). Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: A prospective observational study. BMC Psychiatry, 20(1), 1–7. 10.1186/s12888-019-2374-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-019-2374-2</ArticleId><ArticleId IdType="pmc">PMC7268705</ArticleId><ArticleId IdType="pubmed">32493330</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomar, M., Tawfiq, A. M., Hassan, N., &amp; Palaian, S. (2020). Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status: Challenges and the future. Therapeutic Advances in Drug Safety, 11, 2042098620938595. 10.1177/2042098620938595</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098620938595</ArticleId><ArticleId IdType="pmc">PMC7418468</ArticleId><ArticleId IdType="pubmed">32843958</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., &amp; De Freitas, R. M. (1998). A Bayesian neural network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology, 54(4), 315–321. https://www.ncbi.nlm.nih.gov/pubmed/9696956.
</Citation><ArticleIdList><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach, S. R., Celano, C. M., Noseworthy, P. A., Januzzi, J. L., &amp; Huffman, J. C. (2013). QTc prolongation, Torsades de Pointes, and psychotropic medications. Psychosomatics, 54(1), 1–13. 10.1016/j.psym.2012.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psym.2012.11.001</ArticleId><ArticleId IdType="pubmed">23295003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chorin, E., Hochstadt, A., Viskin, S., Rozovski, U., Havakuk, O., Baranchuk, A., … Rosso, R. (2017). Female gender as independent risk factor of Torsades de Pointes during acquired atrioventricular block. Heart Rhythm, 14(1), 90–95. http://www.sciencedirect.com/science/article/pii/S1547527116307962.
</Citation><ArticleIdList><ArticleId IdType="pubmed">27650425</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa, A., Bosone, D., Cotta Ramusino, M., Perini, G., Ghiotto, N., Zoppi, A., … Fogari, R. (2019). Effect of Evening Bromazepam Administration on blood pressure and heart rate in mild hypertensive patients. Pharmacology, 104(1–2), 1–6. https://www.ncbi.nlm.nih.gov/pubmed/30943497.</Citation><ArticleIdList><ArticleId IdType="pubmed">30943497</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughtrie, A. L., Behr, E. R., Layton, D., Marshall, V., Camm, A. J., &amp; Shakir, S. A. W. (2017). Drugs and life-threatening ventricular arrhythmia risk: Results from the DARE study cohort. BMJ Open, 7(10), e016627. http://bmjopen.bmj.com/content/7/10/e016627.abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652462</ArticleId><ArticleId IdType="pubmed">29042382</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V. … American College of Cardiology Foundation  (2010). Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Journal of the American College of Cardiology, 55(9), 934–947. https://pubmed.ncbi.nlm.nih.gov/20185054; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057430/.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057430</ArticleId><ArticleId IdType="pubmed">20185054</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel, W. (1999). Bayesian data mining in large frequency tables: With an application to the FDA spontaneous reporting system. The American Statistician, 53(3), 177–190. 10.1080/00031305.1999.10474456</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00031305.1999.10474456</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, S. J., Waller, P. C., &amp; Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety, 10(6), 483–486. https://www.ncbi.nlm.nih.gov/pubmed/11828828.
</Citation><ArticleIdList><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration Adverse Event Reporting System (FAERS) Public Dashboard . (n.d.). https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed October 13, 2020.</Citation></Reference><Reference><Citation>Garcia-Elias, A., &amp; Benito, B. (2018). Ion channel disorders and sudden cardiac death. International Journal of Molecular Sciences, 19(3), 692. https://pubmed.ncbi.nlm.nih.gov/29495624; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877553/.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5877553</ArticleId><ArticleId IdType="pubmed">29495624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerold, M., Cavero, I., Riggenbach, H., Wall, M., &amp; Haeusler, G. (1976). Analysis of cardiac chronotropic responses to diazepam and bromazepam in conscious trained dogs. European Journal of Pharmacology, 35(2), 361–368. https://www.ncbi.nlm.nih.gov/pubmed/2483.
</Citation><ArticleIdList><ArticleId IdType="pubmed">2483</ArticleId></ArticleIdList></Reference><Reference><Citation>International Conference on Harmonization (ICH) Guidelines . (n.d.). https://www.ich.org/page/ich-guidelines. Accessed July 14, 2024.</Citation></Reference><Reference><Citation>Iragavarapu, T., &amp; Krishna, K. (2023). Torsades de Pointes complicating acute myocardial infarction, twisting the prognosis. Indian Journal of Clinical Cardiology, 4(3), 208–214. 10.1177/26324636231190247</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/26324636231190247</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen, L., Garnett, C., Luo, M., Targum, S., Sørensen, J. S., &amp; Mehrotra, N. (2018). Quantitative understanding of QTc prolongation and gender as risk factors for Torsade de Pointes. Clinical Pharmacology &amp; Therapeutics, 103(2), 304–309. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002cpt.783.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.783</ArticleId><ArticleId IdType="pubmed">29219167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanba, S. (2004). Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase: How effective is the concomitant use of these drugs? Journal of Psychiatry &amp; Neuroscience, 29(6), 485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524966</ArticleId><ArticleId IdType="pubmed">15644990</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, Q., Ismail, M., Haider, I., &amp; Ali, Z. (2019). Prevalence of the risk factors for QT prolongation and associated drug–drug interactions in a cohort of medical inpatients. Journal of the Formosan Medical Association, 118(1 Pt 1), 109–115. 10.1016/j.jfma.2018.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2018.01.016</ArticleId><ArticleId IdType="pubmed">29458991</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, F., Ismail, M., Khan, Q., &amp; Ali, Z. (2018). Moxifloxacin-induced QT interval prolongation and Torsades de Pointes: A narrative review. Expert Opinion on Drug Safety, 17(10), 1029–1039. 10.1080/14740338.2018.1520837</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2018.1520837</ArticleId><ArticleId IdType="pubmed">30193085</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatib, R., Sabir, F. R., Omari, C., Pepper, C., &amp; Tayebjee, M. H. (2021). Managing drug-induced QT prolongation in clinical practice. Postgraduate Medical Journal, 97(1149), 452–458. 10.1136/postgradmedj-2020-138661</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138661</ArticleId><ArticleId IdType="pmc">PMC8237186</ArticleId><ArticleId IdType="pubmed">33122341</ArticleId></ArticleIdList></Reference><Reference><Citation>Medical Dictionary for Regulatory Activities (MedDRA) . (n.d.). https://www.meddra.org/. Accessed on July 14, 2024.</Citation></Reference><Reference><Citation>Noguchi, Y., Tachi, T., &amp; Teramachi, H. (2021). Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Briefings in Bioinformatics, 22(6), bbab347. 10.1093/bib/bbab347</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab347</ArticleId><ArticleId IdType="pubmed">34453158</ArticleId></ArticleIdList></Reference><Reference><Citation>QTdrugs List &amp; Clinical Factors Associated with Prolonged QTc and/or TdP . (n.d.). https://www.crediblemeds.org/index.php/?cID=328.</Citation></Reference><Reference><Citation>Rahman, A. U., Chowdhury, A., &amp; Jabeen, S. (2018). Changes in ECG among patients with drug induced poisoning in a tertiary care hospital. Bangladesh Medical Research Council Bulletin, 44(3), 160–167. 10.3329/bmrcb.v44i3.39943</Citation><ArticleIdList><ArticleId IdType="doi">10.3329/bmrcb.v44i3.39943</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger, J. Y., Krantz, M. S., Phillips, E. J., &amp; Stone Jr, C. A. (2021). Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS). The Journal of Allergy and Clinical Immunology: In Practice, 9(2), 819–829. 10.1016/j.jaip.2020.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2020.09.021</ArticleId><ArticleId IdType="pmc">PMC7870524</ArticleId><ArticleId IdType="pubmed">32992044</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman, K. J., Lanes, S., &amp; Sacks, S. T. (2004). The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiology and Drug Safety, 13(8), 519–523. https://www.ncbi.nlm.nih.gov/pubmed/15317031.
</Citation><ArticleIdList><ArticleId IdType="pubmed">15317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Diaz, J. C., Frenkel, D., &amp; &amp; Aronow, W. S. (2020). The relationship between atypical antipsychotics drugs, QT interval prolongation, and Torsades de Pointes: Implications for clinical use. Expert Opinion on Drug Safety, 19(5), 559–564. 10.1080/14740338.2020.1745184</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2020.1745184</ArticleId><ArticleId IdType="pubmed">32189527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda, T., Tamon, A., Kadoyama, K., &amp; Okuno, Y. (2013). Data mining of the public version of the FDA Adverse Event Reporting System. International journal of medical sciences, 10(7), 796. 10.7150/ijms.6048</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.6048</ArticleId><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, P. J., &amp; Woosley, R. L. (2016). Predicting the unpredictable: Drug-induced QT prolongation and Torsades de Pointes. Journal of the American College of Cardiology, 67(13), 1639–1650. 10.1016/j.jacc.2015.12.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.12.063</ArticleId><ArticleId IdType="pubmed">27150690</ArticleId></ArticleIdList></Reference><Reference><Citation>Stobaugh, D. J., Deepak, P., &amp; Ehrenpreis, E. D. (2013). Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. Journal of the American Academy of Dermatology, 69(3), 393–398. https://www.sciencedirect.com/science/article/pii/S0190962213004234.
</Citation><ArticleIdList><ArticleId IdType="pubmed">23683730</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, H., Yan, X., Chen, Y., Huang, G., Luo, L., Li, W., … Xi, X. (2024). A real-world pharmacovigilance study of drug-induced QT interval prolongation: Analysis of spontaneous reports submitted to FAERS. Frontiers in Cardiovascular Medicine, 11, 1363382. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1363382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2024.1363382</ArticleId><ArticleId IdType="pmc">PMC11128590</ArticleId><ArticleId IdType="pubmed">38803662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tfelt-Hansen, J., Garcia, R., Albert, C., Merino, J., Krahn, A., Marijon, E., … Haugaa, K. H. (2023). Risk stratification of sudden cardiac death: a review. Europace, 25(8), 8. 10.1093/europace/euad203</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad203</ArticleId><ArticleId IdType="pmc">PMC10450787</ArticleId><ArticleId IdType="pubmed">37622576</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisdale, J. E. (2016). Drug-induced QT interval prolongation and Torsades de Pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada, 149(3), 139–152. 10.1177/1715163516641136</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1715163516641136</ArticleId><ArticleId IdType="pmc">PMC4860751</ArticleId><ArticleId IdType="pubmed">27212965</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandael, E., Vandenberk, B., Vandenberghe, J., Pincé, H., Willems, R., &amp; Foulon, V. (2017). Incidence of Torsade de Pointes in a tertiary hospital population. International Journal of Cardiology, 243, 511–515. 10.1016/j.ijcard.2017.05.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.05.072</ArticleId><ArticleId IdType="pubmed">28576628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandael, E., Vandenberk, B., Vandenberghe, J., Willems, R., &amp; Foulon, V. (2017). Risk factors for QTc-prolongation: Systematic review of the evidence. International Journal of Clinical Pharmacy, 39(1), 16–25. 10.1007/s11096-016-0414-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-016-0414-2</ArticleId><ArticleId IdType="pubmed">28012118</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas, H. M., Rolf, M. G., Wisialowski, T. A., Achanzar, W., Bahinski, A., Bass, A., … Valentin, J.-P. (2021). Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective. Clinical Pharmacology &amp; Therapeutics, 109(2), 310–318. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002cpt.2029.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2029</ArticleId><ArticleId IdType="pmc">PMC7891594</ArticleId><ArticleId IdType="pubmed">32866317</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann, V., Jouven, X., Narayanan, K., Piot, O., Chugh, S. S., Albert, C. M., &amp; Marijon, E. (2020). Association between atrial fibrillation and sudden cardiac death. Circulation Research, 127(2), 301–309. 10.1161/CIRCRESAHA.120.316756</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.316756</ArticleId><ArticleId IdType="pubmed">32833581</ArticleId></ArticleIdList></Reference><Reference><Citation>Woosley, R., Heise, C. W., &amp; Romero, K. A. (n.d.). QTdrugs List. https://www.crediblemeds.org/index.php/?cID=328.</Citation></Reference><Reference><Citation>Woosley, R. L., &amp; Schwartz, P. J. (2020). Drug-induced long QT syndrome and Torsades de Pointes. In El-Sherif Nabil (Ed.), Cardiac Repolarization (pp. 185–200). Springer.</Citation></Reference><Reference><Citation>Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K., &amp; Viskin, S. (2003). Torsade de Pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine, 82(4), 282–290. 10.1097/01.md.0000085057.63483.9b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000085057.63483.9b</ArticleId><ArticleId IdType="pubmed">12861106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorych, I., Madigan, D., Ryan, P., &amp; Bate, A. (2013). Disproportionality methods for pharmacovigilance in longitudinal observational databases. Statistical Methods in Medical Research, 22(1), 39–56. 10.1177/0962280211403602</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280211403602</ArticleId><ArticleId IdType="pubmed">21878461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>